Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE)...
Cancer
Arvinas Announces Changes to its Board of Directors
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new...
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa
PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing...
Oncotelic Participating at Biotechgate Digital Partnering
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival...
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed...
Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topical system) 1.8%
30 million lives now covered by one of the largest national PBMsContinue to work with this PBM to access an...
Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL),...
SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors
Ms. Kalin Joins the Board with Decades of Life Sciences and Healthcare Industry ExperienceNEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE)...
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2...
Bio-Path Holdings Reports Second Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the...
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful...
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Expects interim data by early 2024MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated...
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half...
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including...